Which of the following antiretroviral drugs is not used in HIV & hepatitis B co-infection?

Explanation

## Correct Answer: A. Abacavir Abacavir (ABC) is a nucleoside reverse transcriptase inhibitor (NRTI) that is **not recommended** in HIV/HBV co-infection because it lacks significant anti-hepatitis B activity. In co-infected patients, the antiretroviral regimen must provide dual coverage against both HIV and HBV to prevent resistance and disease progression in either infection. Abacavir has minimal HBV suppression capacity and offers no hepatitis B-specific benefit, making it unsuitable for this population. According to Indian HIV treatment guidelines (NACO/ICMR), co-infected patients require agents with proven dual activity. The standard approach uses nucleos(t)ide reverse transcriptase inhibitors (NRTIs) with intrinsic anti-HBV activity—specifically tenofovir, lamivudine, or emtricitabine—combined with other antiretrovirals. Abacavir's exclusion from co-infection regimens reflects its inability to suppress HBV replication, which would leave hepatitis B untreated and vulnerable to resistance development. This is a critical distinction in Indian clinical practice where HBV co-infection prevalence is significant among HIV-positive populations. ## Why the other options are wrong **B. Tenofovir** — Tenofovir (TDF/TAF) is a nucleotide reverse transcriptase inhibitor with **potent dual activity** against both HIV and HBV. It is a first-line agent in HIV/HBV co-infection regimens per NACO guidelines and provides excellent suppression of both viruses. Tenofovir is specifically chosen for co-infected patients because of its hepatitis B efficacy. **C. Lamivudine** — Lamivudine (3TC) is an NRTI with **proven anti-HBV activity** and is a backbone agent in co-infection therapy. It suppresses both HIV and hepatitis B replication effectively. Lamivudine is universally included in co-infection regimens in Indian practice and is part of standard fixed-dose combinations (FDCs) used in NACO-approved protocols. **D. Emtricitabine** — Emtricitabine (FTC) is a nucleoside analog structurally similar to lamivudine with **equivalent anti-HBV potency**. It provides dual suppression of HIV and HBV and is an acceptable alternative to lamivudine in co-infection regimens. FTC is used in modern antiretroviral combinations for co-infected patients in India. ## High-Yield Facts - **Abacavir has no anti-HBV activity** and must be avoided in HIV/HBV co-infection to prevent hepatitis B resistance and disease progression. - **Tenofovir, lamivudine, and emtricitabine** are the three NRTIs with proven dual HIV and HBV suppression used in co-infection therapy. - **NACO guidelines mandate dual-activity agents** in co-infected patients to prevent selective resistance in either virus. - **Lamivudine resistance in HBV** can emerge if used as monotherapy; combination with tenofovir or other agents prevents this in co-infection. - **Hepatitis B flares** can occur if HBV-active drugs are stopped in co-infected patients, making continuous dual-activity coverage essential. ## Mnemonics **HBV-Active NRTIs: TLE** **T**enofovir, **L**amivudine, **E**mtricitabine — the three NRTIs with anti-HBV activity. Abacavir is NOT in this group. Use this when choosing agents for co-infection: if it's not TLE, it won't cover HBV. **ABC = Absent from co-infection** **A**bacavir is **A**bsent from HIV/HBV co-infection regimens because it lacks **A**nti-HBV activity. Quick memory hook for exam day. ## NBE Trap NBE pairs abacavir with other NRTIs to test whether students know the specific distinction between NRTIs with dual activity (TLE) versus those with HIV-only activity (ABC). The trap is assuming all NRTIs are equivalent in co-infection—they are not. ## Clinical Pearl In Indian HIV clinics, abacavir-based regimens are sometimes used in HBV-negative patients for cost or toxicity reasons, but the moment HBsAg positivity is detected, the regimen must be switched to a TLE-based backbone. Missing this distinction in co-infected patients can lead to HBV resistance and cirrhosis progression—a common clinical pitfall in resource-limited settings. _Reference: NACO HIV Treatment Guidelines (India); Harrison Ch. 197 (HIV/AIDS); KD Tripathi Ch. 49 (Antiretrovirals)_